Annual report pursuant to Section 13 and 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Details Narrative)

v3.19.1
SUMMARY OF SIGNIFICANT ACCOUNTING PRACTICES (Details Narrative)
12 Months Ended
Dec. 22, 2017
Dec. 31, 2018
USD ($)
Number
shares
Dec. 31, 2017
USD ($)
shares
Number of operating segment | Number   1  
Number of reporting unit | Number   1  
Depreciation expense | $   $ 1,706 $ 2,716
Impairment of goodwill | $   $ 1,246,002
Income tax rate 21.00% 23.90% 23.90%
Advance Pharmaceutical Company [Member] | Revenue [Member]      
Concentration risk   0.00% 25.00%
Royalty [Member]      
Revenue | $   $ 0 $ 7,380
Series A Preferred Stock [Member]      
Anti dilutive weighted average number of common shares   8,250,000 5,500,000
Stock Options [Member]      
Anti dilutive weighted average number of common shares   9,594,000 9,594,000
Warrant [Member]      
Anti dilutive weighted average number of common shares   38,999,990 41,029,669
Convertible Debt Securities [Member]      
Anti dilutive weighted average number of common shares   36,407,367 50,419,670